



3 October 2017

**Oxford BioDynamics Plc**  
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

**Oxford BioDynamics announces grant of US patent for its proprietary technology platform, *EpiSwitch*<sup>™</sup>**

Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces the grant of a key patent in the United States by the US Patent and Trademark Office (USPTO) covering *EpiSwitch*<sup>™</sup>, the Company's novel technology platform.

The US patent, number 9777327, covers OBD's proprietary *EpiSwitch*<sup>™</sup> technology designs for high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures, as part of the regulatory genome architecture. As a biomarker modality, chromosome conformations have been shown to deliver highly informative stratifications of complex patient phenotypes, assist in better disease understanding and target identifications, and show high concordance with complex genetic and gene expression profiles. Predictive and prognostic stratifications developed by OBD on the basis of its proprietary *EpiSwitch*<sup>™</sup> technology already offer significant improvements in patient stratifications, significant de-risking of drug discovery and development, and upgraded regulatory and market protection.

This patent will extend coverage of Oxford BioDynamics' proprietary technology platform, *EpiSwitch*<sup>™</sup>, into another important market for the Company. Counterparts to this patent have already been granted in Europe, China, Japan, Australia, Hong Kong, New Zealand, Singapore and South Africa.

**Christian Hoyer Millar, CEO of Oxford BioDynamics, commented:**

*"The US is a key target market for Oxford BioDynamics and we are delighted to announce the grant of this patent covering use of EpiSwitch<sup>™</sup> in this region. The grant of this patent in the US is a significant milestone for the Company. It adds further strength to our global intellectual property portfolio as we position the Company for future growth. With a number of significant achievements in patients' stratifications that OBD has delivered already, we welcome this significant milestone as recognition of our proprietary EpiSwitch<sup>™</sup> technology. We believe EpiSwitch<sup>™</sup> is a valuable and leading industry solution capable of characterising structural modifications to genome architecture that have a profound effect on health."*

**For further details contact:**

**Oxford BioDynamics Plc** **+44 (0)1865 518910**  
Christian Hoyer Millar, CEO  
Paul Stockdale, CFO

**Stifel Nicolaus Europe Limited** **+44 (0)20 7710 7600**  
**Nominated Advisor and Broker**  
David Arch  
Jonathan Senior  
Peter Lees  
Ben Maddison

**Shore Capital** **+44 (0)20 7408 4090**  
**Joint Broker**  
Bidhi Bhoma

Edward Mansfield

**FTI Consulting**  
**Financial Public Relations Advisor**

**+44 (0)20 3727 1000**

Julia Phillips  
Brett Pollard  
Natalie Garland-Collins

***Notes for Editors***

**About Oxford BioDynamics Plc**

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, *EpiSwitch*<sup>™</sup>, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, *EpiSwitch*<sup>™</sup> can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com).